Hepion Pharmaceuticals, Inc. (HEPA) |
|
0.6912 -0.012 (-1.71%)
|
08-19 00:41 |
|
Open: |
0.69 |
Pre. Close: |
0.7032 |
|
High:
|
0.7069 |
Low:
|
0.6813 |
|
Volume:
|
115,454 |
Market Cap:
|
53(M) |
|
|
|
|
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.74 - 0.75 |
0.75 - 0.75 |
|
Low:
|
0.67 - 0.68 |
0.68 - 0.68 |
|
Close:
|
0.7 - 0.7 |
0.7 - 0.71 |
|
Technical analysis |
as of: 2022-08-18 3:53:18 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.88 One year: 1.03 |
| Support: |
Support1: 0.59 Support2: 0.49 |
| Resistance: |
Resistance1: 0.75 Resistance2: 0.88 |
| Pivot: |
0.65  |
| Moving Average: |
MA(5): 0.71  MA(20): 0.63
MA(100): 0.76 MA(250): 1.08 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 81.2 %D(3): 85.5 |
| RSI: |
RSI(14): 57.4 |
| 52-week: |
High: 1.85 Low: 0.49 |
| Average Vol(K): |
3-Month: 180 (K) 10-Days: 215 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HEPA ] has closed below upper band by 37.7%. Bollinger Bands are 70.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 17 Aug 2022
Medical Grade HEPA Filter Air Purifier Now Available by Camfil - Financial Post
Tue, 16 Aug 2022
High-Efficiency Particulate Air (HEPA) Filter Membrane Market Forecast 2030 : Analysis of The Key Players, Gro - openPR
Mon, 15 Aug 2022
Save 33% on LEVOIT’s Vital 100 Air Purifier with H13 HEPA Filter at new low of $80 - 9to5Toys
Fri, 12 Aug 2022
Medical Gel Seal HEPA Filter market: Strategies to Adopt to Sustain Market Hold | Airepure Australia Pty Ltd, - openPR
Thu, 11 Aug 2022
This Portable Air Purifier Is on Sale for $35 at Amazon - PEOPLE
Wed, 10 Aug 2022
Is Hepion Pharmaceuticals Inc (HEPA) Stock About to Get Hot Wednesday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
76 (M) |
| Shares Float |
76 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
12.1 (%) |
|
Shares Short
|
905 (K) |
|
Shares Short P.Month
|
1,060 (K) |
Stock Financials |
|
EPS
|
-0.44 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.11 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-18 |
|
Return on Equity (ttm)
|
-33 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.42 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-34 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-1.58 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.62 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.56 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-02 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
